PRIVIA HEALTH GROUP INC (PRVA) Stock Fundamental Analysis
NASDAQ:PRVA - Nasdaq - US74276R1023 - Common Stock - Currency: USD
PRVA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 103 industry peers in the Health Care Providers & Services industry. No worries on liquidiy or solvency for PRVA as it has an excellent financial health rating, but there are worries on the profitability. PRVA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PRVA had positive earnings in the past year.
PRVA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PRVA reported negative net income in multiple years.
PRVA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
PRVA has a Return On Assets (1.32%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of 2.37%, PRVA is in line with its industry, outperforming 54.37% of the companies in the same industry.
The Return On Invested Capital of PRVA (2.00%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.32% | ||
| ROE | 2.37% | ||
| ROIC | 2% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRVA's Profit Margin of 0.87% is in line compared to the rest of the industry. PRVA outperforms 54.37% of its industry peers.
PRVA's Profit Margin has declined in the last couple of years.
With a Operating Margin value of 1.19%, PRVA perfoms like the industry average, outperforming 44.66% of the companies in the same industry.
In the last couple of years the Operating Margin of PRVA has declined.
PRVA's Gross Margin of 10.09% is on the low side compared to the rest of the industry. PRVA is outperformed by 76.70% of its industry peers.
In the last couple of years the Gross Margin of PRVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.19% | ||
| PM (TTM) | 0.87% | ||
| GM | 10.09% |
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PRVA is destroying value.
PRVA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PRVA has more shares outstanding
There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 4.94 indicates that PRVA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.94, PRVA belongs to the top of the industry, outperforming 80.58% of the companies in the same industry.
There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.94 |
ROIC/WACC0.22
WACC8.93%
2.3 Liquidity
A Current Ratio of 1.88 indicates that PRVA should not have too much problems paying its short term obligations.
PRVA has a Current ratio of 1.88. This is in the better half of the industry: PRVA outperforms 68.93% of its industry peers.
A Quick Ratio of 1.88 indicates that PRVA should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.88, PRVA is in the better half of the industry, outperforming 72.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 |
3. Growth
3.1 Past
The earnings per share for PRVA have decreased strongly by -20.00% in the last year.
PRVA shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.43% yearly.
Looking at the last year, PRVA shows a small growth in Revenue. The Revenue has grown by 6.79% in the last year.
The Revenue has been growing by 17.17% on average over the past years. This is quite good.
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%50%
Revenue 1Y (TTM)6.79%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%12.84%
3.2 Future
The Earnings Per Share is expected to grow by 62.51% on average over the next years. This is a very strong growth
Based on estimates for the next years, PRVA will show a small growth in Revenue. The Revenue will grow by 0.21% on average per year.
EPS Next Y90.75%
EPS Next 2Y76.06%
EPS Next 3Y62.51%
EPS Next 5YN/A
Revenue Next Year11.86%
Revenue Next 2Y11.19%
Revenue Next 3Y11.67%
Revenue Next 5Y0.21%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
PRVA is valuated quite expensively with a Price/Earnings ratio of 182.67.
The rest of the industry has a similar Price/Earnings ratio as PRVA.
PRVA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.28.
A Price/Forward Earnings ratio of 64.29 indicates a quite expensive valuation of PRVA.
The rest of the industry has a similar Price/Forward Earnings ratio as PRVA.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, PRVA is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 182.67 | ||
| Fwd PE | 64.29 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PRVA is valued a bit more expensive than 62.14% of the companies in the same industry.
61.16% of the companies in the same industry are more expensive than PRVA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.58 | ||
| EV/EBITDA | 79.33 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PRVA does not grow enough to justify the current Price/Earnings ratio.
PRVA's earnings are expected to grow with 62.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.01
PEG (5Y)24.57
EPS Next 2Y76.06%
EPS Next 3Y62.51%
5. Dividend
5.1 Amount
No dividends for PRVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
21.92
-0.62 (-2.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners99.99%
Inst Owner Change1.52%
Ins Owners1.86%
Ins Owner Change0.88%
Market Cap2.67B
Analysts84.29
Price Target31.21 (42.38%)
Short Float %3.01%
Short Ratio4.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.31%
Min EPS beat(2)-40.79%
Max EPS beat(2)-37.83%
EPS beat(4)0
Avg EPS beat(4)-38.4%
Min EPS beat(4)-40.79%
Max EPS beat(4)-36.27%
EPS beat(8)1
Avg EPS beat(8)-32.84%
EPS beat(12)5
Avg EPS beat(12)107.25%
EPS beat(16)8
Avg EPS beat(16)62.22%
Revenue beat(2)2
Avg Revenue beat(2)4.34%
Min Revenue beat(2)0.75%
Max Revenue beat(2)7.92%
Revenue beat(4)4
Avg Revenue beat(4)2.8%
Min Revenue beat(4)0.75%
Max Revenue beat(4)7.92%
Revenue beat(8)8
Avg Revenue beat(8)2.56%
Revenue beat(12)8
Avg Revenue beat(12)-7.79%
Revenue beat(16)10
Avg Revenue beat(16)-10%
PT rev (1m)3.38%
PT rev (3m)6.96%
EPS NQ rev (1m)0.46%
EPS NQ rev (3m)-16.28%
EPS NY rev (1m)-0.69%
EPS NY rev (3m)-20.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.08%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.91%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 182.67 | ||
| Fwd PE | 64.29 | ||
| P/S | 1.48 | ||
| P/FCF | 22.58 | ||
| P/OCF | 22.58 | ||
| P/B | 4.05 | ||
| P/tB | 6.52 | ||
| EV/EBITDA | 79.33 |
EPS(TTM)0.12
EY0.55%
EPS(NY)0.34
Fwd EY1.56%
FCF(TTM)0.97
FCFY4.43%
OCF(TTM)0.97
OCFY4.43%
SpS14.77
BVpS5.41
TBVpS3.36
PEG (NY)2.01
PEG (5Y)24.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.32% | ||
| ROE | 2.37% | ||
| ROCE | 3% | ||
| ROIC | 2% | ||
| ROICexc | 5.87% | ||
| ROICexgc | N/A | ||
| OM | 1.19% | ||
| PM (TTM) | 0.87% | ||
| GM | 10.09% | ||
| FCFM | 6.57% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-10.22%
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
F-Score6
Asset Turnover1.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 111.34 | ||
| Cash Conversion | 412.04% | ||
| Profit Quality | 757.69% | ||
| Current Ratio | 1.88 | ||
| Quick Ratio | 1.88 | ||
| Altman-Z | 4.94 |
F-Score6
WACC8.93%
ROIC/WACC0.22
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%50%
EPS Next Y90.75%
EPS Next 2Y76.06%
EPS Next 3Y62.51%
EPS Next 5YN/A
Revenue 1Y (TTM)6.79%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%12.84%
Revenue Next Year11.86%
Revenue Next 2Y11.19%
Revenue Next 3Y11.67%
Revenue Next 5Y0.21%
EBIT growth 1Y45%
EBIT growth 3YN/A
EBIT growth 5Y1.07%
EBIT Next Year515.6%
EBIT Next 3Y106.09%
EBIT Next 5Y64.58%
FCF growth 1Y202.94%
FCF growth 3Y26.09%
FCF growth 5Y42.42%
OCF growth 1Y202.4%
OCF growth 3Y25.67%
OCF growth 5Y35.01%